Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aflibercept biosimilar - Alvotech

Next Previous
Drug Profile

Aflibercept biosimilar - Alvotech

Alternative Names: Afiveg; Aflibercept BS; AVT-06; AVT-29; Mynzepli; Vgenfli

Latest Information Update: 20 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alvotech
  • Developer Alvotech; Teva Pharmaceutical Industries
  • Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Choroidal neovascularisation; Retinal disorders; Retinal oedema; Retinal vein occlusion; Wet age-related macular degeneration

Most Recent Events

  • 18 Mar 2026 Alvotech plans a phase III trial for Diabetic macular oedema(In, adults, In the elderly) in Georgia, India, Latvia, Ukraine, Czech Republic, Slovakia, Bulgaria, Hungary, Poland(Intravitreal) in March 2026 (EUCT2025-522231-34-00)(CTIS2025-522231-34-00)
  • 29 Jan 2026 Alvotech settled all patent disputes with Regeneron and Bayer for Aflibercept biosimilar
  • 29 Jan 2026 Alvotech anticipates launch for Aflibercept biosimilar in Japan in November 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top